Posts

When Is Hormone Therapy Really Worth It?

Image
For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit - The ASCO Post New landmark research redraws the map on androgen deprivation therapy — who truly benefits, how long treatment should last, and what the very real side effects mean for your quality of life. IPCSG Medical Education Staff  |  Sources: The Lancet, JAMA Oncology, ASCO GU 2026, NCI, ASCO, UCLA Health, University Hospitals Seidman Cancer Center, European Urology Oncology, Scientific Reports Bottom Line Up Front (BLUF) Androgen deprivation therapy (ADT) — hormone therapy that lowers testosterone — has long been a cornerstone of prostate cancer treatment, but three major new analyses published in early 2026 have clarified when it actually saves lives and when it may do more harm than good. For men receiving salvage radiation after prostatectomy, ADT appears to offer a meaningful survival benefit only if their pr...
Post a Comment
Read more

Vaccines Against Prostate Cancer:

Image
Cancer vaccines could transform treatment and prevention – but misinformation about mRNA vaccines threatens their potential Informed Prostate Cancer Support Group March 2026  |  Special Feature: Cancer Immunotherapy Feature Article · Immunotherapy From Proven Therapy to the mRNA Frontier A major new immunotherapy is heading toward FDA approval, mRNA cancer vaccines are entering pivotal trials, and a promising "tumor autovaccination" strategy has shown proof of concept — here is what the latest science means for men with prostate cancer. Prepared for IPCSG Members  |  March 2026  |  Reviewed against published peer-reviewed literature and official regulatory releases BLUF — Bottom Line Up Front The idea of using the immune system itself to fight prostate cancer is no longer just a promise — it is increasingly a reality. One therapeutic vaccine, Provenge® (sipuleucel-T), has been FDA-approve...
Post a Comment
Read more

A Better Safety Net: How PSMA PET/MRI Is Catching Hidden High-Risk Disease in Men Choosing Active Surveillance or Focal Therapy

Image
A Pilot Study of 18F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease - Alam - The Prostate - Wiley Online Library Informed Prostate Cancer Support Group (IPCSG) Spring 2026  |  Volume XXIV  |  Imaging & Early-Stage Management Featured Research Review A landmark Northwestern University pilot trial — and a wave of supporting international research — shows that this advanced scan can find dangerous tumors standard MRI misses, changing one-in-three patients' treatment plans and dramatically boosting confidence for everyone involved. Compiled for the IPCSG Newsletter | March 2026 | Based on peer-reviewed research and FDA-approved clinical evidence Bottom Line Up Front (BLUF) A new pilot clinical trial from Northwestern University found that a next-generation scan — ¹⁸F-rhPSMA-7.3 PET/MRI (bran...
Post a Comment
Read more

When Cancer Moves Without Warning:

Image
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy - Tsutsumi - The Prostate - Wiley Online Library Informed Prostate Cancer Support Group IPCSG Newsletter  ·  Patient Education Series Spring 2026 Vol. 28 / Treatment Monitoring Treatment Monitoring  ·  Advanced Prostate Cancer The Problem of PSA-Silent Progression A new study from Japan, along with a growing body of international research, reveals that a significant number of men on today's powerful hormone therapies can have cancer that spreads on imaging — even while their PSA levels look perfectly controlled. What does this mean for how you are being monitored? IPCSG Newsletter  ·  Research Summary for Patients and Families Bottom Line Up Front (BLUF) A critical gap in standard prostate cancer monitoring...
Post a Comment
Read more